Zai Lab Ltd at Citi BioTech C-Suite Fireside Chat Series (Virtual) Transcript
I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. This is a continuation of our newly introduced C-suite series where we feature management from some of our covered companies for a 1-hour discussion about the pipeline and other topics.
So it's my great pleasure to have with me this morning, Josh Smiley, who is the COO of Zai Lab. Josh started in August of 2022 after a 26-year career at Lilly. (Operator Instructions) So Josh, welcome. Thank you so much for taking the time to speak with us for an hour. I appreciate it.
Questions & Answers
I think a lot of people are familiar with Zai Lab, but I think a lot of people also aren't. So I think maybe to start with, if you could just outline the strategic vision for the company over the next, say, 5 or 10 years. How do you see the mission evolving, both in the pipeline as well as the commercial side? And how do you see the transformation of Zai
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |